To further determine the association between KMO and tumor progression, KMO expression in CMTs was analyzed by immunohistochemistry and scored by immunoreactive scoring (IRS) under the conditions listed in Table 1: Primers for canine IDO, KMO, actin, and HPRT. This evidence concerns the gene IDO1 and neoplasm.